Document is current

Any future updates will be listed below

A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib

Crossref DOI link: https://doi.org/10.1038/s41598-025-85831-4

Published Online: 2025-01-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark